Dosing & Administration

Recommended approach to dosing:
Start with it. Stay with it.®

At early signs of degenerative joint disease, veterinarians can administer Adequan® i.m. at the approved dose (500 mg) to achieve improvement shown in studies.1,2 After the initial series, veterinarians and owners alike should keep monitoring the horse’s joint health and mobility. Veterinarians may repeat the 1•4•7 series as needed upon recurrence of the clinical signs of DJD.

Adequan Equine veterinarian giving horse injection
Adequan Equine ideal dosing frequency graphic

Based on findings in a Dose Titration Response Study,
below is the recommended dosing interval for Adequan® i.m.1

For example:
Adequan Equine ideal dosing calendar graphic

INDICATIONS

Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

Quickly reaches your horse’s joints to deliver relief.

After intramuscular administration, Adequan® i.m. is well absorbed, goes to work fast and keeps working for up to 96 hours.2

Adequan Equine horse healthy joint graphic

Hyaluronic Acid (HA) levels nearly doubled at 48 hours with significant increases noted from 24 up to 96 hours.2
Clinical significance of the above results is unknown.

Reduced lameness. Improved carpal flexion.1

In a Dose Titration Study, the benefits of adhering to the labeled dosing regimen delivered over 50% improvement in maximum carpal flexion.1

Adequan Equine carpal flexion improvement graph

*A placebo-controlled, blinded dose titration study was conducted in a total of 36 healthy, mature horses that were either Quarter horses or Thoroughbreds. An induced adjuvant carpitis in the horse was used to assess the dose and efficacy of the intramuscular administration of Adequan® i.m. The adjuvant induced arthritis was produced with a single intraarticular injection of 0.5 mL of Freunds adjuvant. The various treatments comprised sterile saline solution as a placebo control and 50 mg, 125 mg, 250 mg, 500 mg and1,000 mg of the active drug substance Adequan® i.m. dissolved in sterile water. Injections were given every 4 days for a total of 7 injections. Treatment followed a 10 day acclimation period and a five day model induction period.

Hear how Adequan® i.m. is delivering results for veterinarians, trainers and horse owners.

INDICATIONS
Adequan® i.m. (polysulfated glycosaminoglycan) is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
IMPORTANT SAFETY INFORMATION There are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan. Studies have not been conducted to establish safety in breeding horses. WARNING: Do not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children. CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. For full prescribing information, click here.
1. Freedom of Information Summary, Adequan® i.m. NADA 140-901, https://animaldrugsatfda.fda.gov/adafda/app/search /public/document/downloadFoi/2489
2. Burba DJ, Collier MA, DeBault LE, Hanson-Painton O, Thompson HC, Holder CL: In vivo kinetic study on uptake and distribution of intramuscular tritium-labeled polysulfated glycosaminoglycan in equine body fluid compartments and articular cartilage in an osteochondral defect model. J Equine Vet Sci 1993; 13: 696-703.

Let’s stay in touch.

Be the first to hear about important news and product information!
First, select the one that best describes you.
Then we'll take you to our sign-up page.

EQUINE VETERINARY
PROFESSIONAL
HORSE OWNER
AMERICAN REGENT ANIMAL HEALTH
About Us Our Brands